Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Pipeline Review, H2 2016

Published: Sep, 2016 | Pages: 62 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Pipeline Review, H2 2016', provides in depth analysis on Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) targeted pipeline therapeutics. 

The report provides comprehensive information on the Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: 
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) 
- The report reviews Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) 
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) Overview 8
Therapeutics Development 9
Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Products under Development by Stage of Development 9
Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Products under Development by Therapy Area 10
Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Products under Development by Indication 11
Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Pipeline Products Glance 12
Late Stage Products 12
Early Stage Products 13
Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Products under Development by Companies 14
Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Therapeutics Assessment 16
Assessment by Monotherapy/Combination Products 16
Assessment by Mechanism of Action 17
Assessment by Route of Administration 18
Assessment by Molecule Type 19
Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Companies Involved in Therapeutics Development 20
Amgen Inc. 20
Array BioPharma Inc. 21
Astellas Pharma Inc. 22
CymaBay Therapeutics, Inc. 23
Daiichi Sankyo Company, Limited 24
F. Hoffmann-La Roche Ltd. 25
GlaxoSmithKline Plc 26
Hyundai Pharmaceutical Co., Ltd. 27
LG Life Science LTD. 28
Merck & Co., Inc. 29
Novartis AG 30
Sanwa Kagaku Kenkyusho Co., Ltd. 31
Taisho Pharmaceutical Holdings Co., Ltd. 32
Takeda Pharmaceutical Company Limited 33
Yuhan Corporation 34
Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Drug Profiles 35
17-i - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
ARRY-981 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
AS-1669058 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
DA-1241 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
DS-8500 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
GSK-2041706 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
HD-0471042 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
HD-0471953 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
HOB-047 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
LC-34AD3 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
MBX-2982 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
Small Molecule to Agonize GPR119 for Type 2 Diabetes - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
Small Molecule to Agonize GPR119 for Type II Diabetes - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
Small Molecule to Agonize GPR119 for Undisclosed Indication - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
Small Molecule to Agonize GPR119 Receptor for Undisclosed Indication - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
Small Molecules to Agonize GPR119 for Metabolic Disorders - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
Small Molecules to Agonize GPR119 for Type II Diabetes - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
Small Molecules to Agonize GPR119 Receptor for Type 2 Diabetes - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
Small Molecules to Agonize GPR119 Receptor for Type II Diabetes - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
YH-18420 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Dormant Projects 56
Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Discontinued Products 58
Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Featured News & Press Releases 59
Nov 05, 2009: Metabolex Closes $8.6 Million Financing Round 59
Nov 12, 2008: Metabolex Announces Positive Results From Phase 1a Clinical Trial Of MBX-2982 59
Mar 26, 2008: Metabolex, Inc. Initiates Phase 1 Trial Of MBX-2982 60
Appendix 61
Methodology 61
Coverage 61
Secondary Research 61
Primary Research 61
Expert Panel Validation 61
Contact Us 61
Disclaimer 62

List of Tables

Number of Products under Development for, H2 2016 9
Number of Products under Development by Therapy Area, H2 2016 10
Number of Products under Development by Indication, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Early Stage Products, H2 2016 13
Number of Products under Development by Companies, H2 2016 14
Products under Development by Companies, H2 2016 15
Assessment by Monotherapy/Combination Products, H2 2016 16
Number of Products by Stage and Mechanism of Action, H2 2016 17
Number of Products by Stage and Route of Administration, H2 2016 18
Number of Products by Stage and Molecule Type, H2 2016 19
Pipeline by Amgen Inc., H2 2016 20
Pipeline by Array BioPharma Inc., H2 2016 21
Pipeline by Astellas Pharma Inc., H2 2016 22
Pipeline by CymaBay Therapeutics, Inc., H2 2016 23
Pipeline by Daiichi Sankyo Company, Limited, H2 2016 24
Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 25
Pipeline by GlaxoSmithKline Plc, H2 2016 26
Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2016 27
Pipeline by LG Life Science LTD., H2 2016 28
Pipeline by Merck & Co., Inc., H2 2016 29
Pipeline by Novartis AG, H2 2016 30
Pipeline by Sanwa Kagaku Kenkyusho Co., Ltd., H2 2016 31
Pipeline by Taisho Pharmaceutical Holdings Co., Ltd., H2 2016 32
Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 33
Pipeline by Yuhan Corporation, H2 2016 34
Dormant Projects, H2 2016 56
Dormant Projects (Contd..1), H2 2016 57
Discontinued Products, H2 2016 58